Pierre Giglio to Brain Neoplasms
This is a "connection" page, showing publications Pierre Giglio has written about Brain Neoplasms.
Connection Strength
3.186
-
Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report. Neuroradiol J. 2019 Oct; 32(5):317-327.
Score: 0.492
-
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
Score: 0.290
-
Cyclooxygenase-2 inhibitors in glioma therapy. Am J Ther. 2004 Mar-Apr; 11(2):141-3.
Score: 0.170
-
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023 01 01; 9(1):112-121.
Score: 0.157
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol. 2022 06 11; 15(1):80.
Score: 0.151
-
Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022 05; 170:21-26.
Score: 0.149
-
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol. 2022 Jan; 156(2):399-406.
Score: 0.146
-
Primary central nervous system lymphoma masquerading as herpes encephalitis: clinical, magnetic resonance imaging, and pathologic findings. Am J Med Sci. 2002 Jan; 323(1):59-61.
Score: 0.146
-
Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 10 06; 22(11):105.
Score: 0.144
-
Intraoperative 3?T MRI is more correlative to residual disease extent than early postoperative MRI. J Neurooncol. 2021 Sep; 154(3):345-351.
Score: 0.143
-
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. PLoS One. 2020; 15(12):e0244383.
Score: 0.136
-
False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences. Am J Clin Oncol. 2020 11; 43(11):802-805.
Score: 0.135
-
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
Score: 0.134
-
Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Rev Neurother. 2019 07; 19(7):663-677.
Score: 0.122
-
Perilesional apparent diffusion coefficient in the preoperative evaluation of glioma grade. Clin Imaging. 2018 Nov - Dec; 52:88-94.
Score: 0.115
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.088
-
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013 Aug; 114(1):43-50.
Score: 0.081
-
Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab Brain Dis. 2013 Sep; 28(3):355-66.
Score: 0.080
-
Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012 Jun; 37(6):1192-200.
Score: 0.073
-
Concomitant lymphoma and cryptococcosis in a patient with acquired immune deficiency syndrome. Am J Med Sci. 2010 Oct; 340(4):340-2.
Score: 0.067
-
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol. 2009 Jul; 93(3):343-8.
Score: 0.060
-
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
Score: 0.056
-
Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer. 2007 Feb 15; 109(4):761-6.
Score: 0.052